EUCTR2007-005912-23-GB进行中（未招募）1 期
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, ACTIVE-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CELECOXIB (CELEBREX®) AND INDOMETHACIN IN THE TREATMENT OF MODERATE TO SEVERE ACUTE GOUTY ARTHRITIS
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Inc.
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Male and female patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- •1. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study;
- •2. At least 18 years of age or older;
- •3. Acute gouty arthritis meeting the American College of Rheumatology (ACR) criteria
- •for acute arthritis of primary gout;
- •4. Onset of pain from an acute gouty arthritis attack within 48 hours prior to
- •Screening/Baseline (Visit 1);
- •5. A rating of moderate, severe, or extreme (2, 3, or 4, respectively) on the Patient’s
- •Assessment of Pain Intensity in the Index Joint (5-point scale: 0-4) at Screening/Baseline;
- •6. Candidate for daily therapy with an NSAID and/or analgesic, in the investigator’s
- •7. Patients who are willing and able to comply with scheduled visits, treatment plan,
- •laboratory tests, and other study procedures;
- •8. If the patient is female and of childbearing potential, she must be using adequate
- •contraception since her last menses, continue using adequate contraception during the study, not lactating, and must have had a negative urine pregnancy test confirmed at Screening/Baseline. (Note: Women who are post-menopausal or are surgically sterilized for less than 2 years, will also require a urine pregnancy test at
- •Screening/Baseline).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients presenting with any of the following are excluded from participation in the study:
- •1. Diagnosis of any other type of arthritis including those types suspected of being infectious in origin or presence of any acute trauma in the Index Joint
- •2. Acute polyarticular gout (involving greater than 4 joints) or chronic gout
- •3. Use of any NSAID or analgesic therapy to treat the current acute gouty arthritis attack
- •4. Patients on any of the following medications are specifically excluded:
- •? Chronic NSAID and/or analgesic therapy (defined as >1 week) within 5 half lives (for the particular agent) prior to Screening/Baseline
- •? Acetylsalicylic acid (ASA) at doses of >325 mg/day
- •? Oral or injectable (including intra-articular) corticosteroids administered within 2 weeks of Screening/Baseline
- •? Intra-articular injections of hyaluronic acid in the Index Joint
- •? Lithium and anticoagulants (such as warfarin, heparin, low molecular weight heparin)
- •? Local anesthetics, including regional blocks within 48 hours prior to Screening/Baseline and for the duration of the study
- •? Any other investigational medication within 30 days prior to Screening/Baseline or patient is scheduled to receive an investigational drug during the course of this study
- •5. History of acute or chronic gouty arthritis that has been unresponsive to NSAIDs
- •6. Any significant, uncontrolled disease, or condition which, in the opinion of the investigator, would contraindicate study participation or confound interpretation of the results
- •7. Known laboratory abnormality; including AST, ALT, or blood urea nitrogen (BUN) >1.5 × the upper limit of the reference range, creatinine >1.5 mg/dL, or any other laboratory abnormality that in the opinion of the investigator would contraindicate study participation [Results from the analyses of complete blood count (CBC), blood chemistries, and/or urinalysis obtained within 6 months prior to Screening/Baseline must be available for determination of eligibility]
- •8. History of known alcohol or other substance abuse (in the investigator’s opinion) within 2 years of Screening/Baseline
- •9. Diagnosed as having or has been treated for esophageal, gastric, pyloric channel, or duodenal ulceration within 60 days prior to Screening/Baseline
- •10. Known hypersensitivity allergy or hypersensitivity to sulfonamides, COX-2 selective inhibitors (including celecoxib), aspirin or NSAIDS (including indomethacin)
- •11. Active GI disease (eg, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, gastroesophageal reflux disease), a chronic or acute renal or hepatic disorder, a significant coagulation defect, or any condition that in the investigator’s opinion might preclude the use of an NSAID
- •12. Active malignancy of any type, including suspected metastases, or treatment for cancer (ie, surgery, chemotherapy, radiation therapy, etc.), or remission from any cancer other than basal cell carcinoma for less than 2 years prior to Screening/Baseline
- •13. Patient has symptoms, signs or treatment for congestive heart failure (NYHA Classification II-IV) or known left ventricular dysfunction with ejection fraction <40% (App
研究者
相似试验
已完成
不适用
Celebrex In Acute Gouty Arthritis StudyPER-062-08PFIZER S.A.,
进行中（未招募）
不适用
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, ACTIVE-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CELECOXIB (CELEBREX) AND INDOMETHACIN IN THE TREATMENT OF MODERATE TO SEVERE ACUTE GOUTY ARTHRITIS - NDEUCTR2007-005912-23-ITPFIZER450
进行中（未招募）
1 期
A randomized, double-blind double-dummy Phase 3 study performed at multiple study sites to evaluate the safety, efficacy and tolerability of the combinational product Carbavance (Meropenem/RPX7009) in comparison to Piperacillin/Tazobactam which is already approved in many countries to treat patients with complicated urinary tract infections, including acute pyelonephritis, in adults.complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) with or without concurrent bacteremiaMedDRA version: 18.1Level: PTClassification code 10037597Term: Pyelonephritis acuteSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-000545-78-SIRempex Pharmaceuticals, Inc.500
进行中（未招募）
1 期
A randomized, double-blind double-dummy Phase 3 study performed at multiple study sites to evaluate the safety, efficacy and tolerability of the combinational product Carbavance (Meropenem/RPX7009) in comparison to Piperacillin/Tazobactam which is already approved in many countries to treat patients with complicated urinary tract infections, including acute pyelonephritis, in adults.complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) with or without concurrent bacteremiaMedDRA version: 18.1Level: PTClassification code 10037597Term: Pyelonephritis acuteSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-000545-78-BGRempex Pharmaceuticals, Inc.500
未知
不适用
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BELIMUMAB (HGS 1006) ADMINISTERED SUBCUTANEOUSLY (SC) TO SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).PER-046-12HUMAN GENOME SCIENCES, INC.,